Evolus, Inc. (EOLS)

NASDAQ: EOLS · IEX Real-Time Price · USD
6.99
0.29 (4.25%)
Jan 28, 2022 3:15 PM EST - Market open
Market Cap388.21M
Revenue (ttm)85.59M
Net Income (ttm)-139.33M
Shares Out55.58M
EPS (ttm)-3.15
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume518,760
Open6.60
Previous Close6.70
Day's Range6.59 - 7.12
52-Week Range5.06 - 17.38
Beta2.38
AnalystsBuy
Price Target15.14 (+116.8%)
Earnings Daten/a

About EOLS

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was founded in 2012 and is headquartered in Newport Beach, California.

IndustryPharmaceuticals
IPO DateFeb 8, 2018
CEODavid Moatazedi
Employees149
Stock ExchangeNASDAQ
Ticker SymbolEOLS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for Evolus stock is "Buy." The 12-month stock price forecast is 15.14, which is an increase of 116.75% from the latest price.

Price Target
$15.14
(116.75% upside)
Analyst Consensus: Buy

News

Evolus Expects Q4 FY21 Sales Better Than Anticipated, Issues FY22 Guidance

Evolus Inc (NASDAQ: EOLS) has posted interim Q4 sales of approximately $34.7 million (better than the consensus of $30.87 million), up 68% Y/Y, driven by higher volumes and a higher average selling pric...

2 days ago - Benzinga

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2021 Net Revenue and Provides 2022 Guidance

NEWPORT BEACH, Calif.--(BUSINESS WIRE)---- $EOLS--Evolus announces its preliminary, unaudited net revenue and cash position as of and for the fourth quarter and full-year ended December 31, 2021.

2 days ago - Business Wire

Evolus Expands Board of Directors With Appointment of Digital and Beauty Innovator Brady Stewart

NEWPORT BEACH, Calif.--(BUSINESS WIRE)---- $EOLS--Evolus announces that it has further strengthened and diversified its Board of Directors with the appointment of Brady Stewart.

3 weeks ago - Business Wire

Evolus Joins Nasdaq Biotechnology Index

NEWPORT BEACH, Calif.--(BUSINESS WIRE)---- $EOLS--Evolus announces that its common stock has been selected for inclusion in the Nasdaq Biotechnology Index effective today.

1 month ago - Business Wire

Evolus Enters Into $125 Million Credit Facility with Pharmakon Advisors

NEWPORT BEACH, Calif.--(BUSINESS WIRE)---- $EOLS--Evolus, a performance beauty company, has entered into a $125 million term loan financing facility with funds managed by Pharmakon Advisors, L.P.

1 month ago - Business Wire

Evolus, Inc. (EOLS) Reports Q3 Loss, Lags Revenue Estimates

Evolus, Inc. (EOLS) delivered earnings and revenue surprises of 18.75% and -1.08%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Evolus Reports Third Quarter 2021 Results and Provides Business Update

NEWPORT BEACH, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (Nasdaq: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today rep...

2 months ago - GlobeNewsWire

Evolus Initiates Phase II Program with “Extra Strength” Dose for Extended Duration

NEWPORT BEACH, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (Nasdaq: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today ann...

2 months ago - GlobeNewsWire

Evolus Announces Appointment of Jessica Novak as Senior Vice President, Human Resources

NEWPORT BEACH, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today ann...

2 months ago - GlobeNewsWire

Evolus, Inc. (EOLS) Expected to Beat Earnings Estimates: Should You Buy?

Evolus, Inc. (EOLS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

Evolus to Report Third Quarter 2021 Results and Provide Business Update

NEWPORT BEACH, Calif., Oct. 22, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today ann...

3 months ago - GlobeNewsWire

Evolus Announces Participation in September Investment Conferences

NEWPORT BEACH, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today an...

4 months ago - GlobeNewsWire

Evolus, Inc. (EOLS) Reports Q2 Loss, Tops Revenue Estimates

Evolus, Inc. (EOLS) delivered earnings and revenue surprises of -12.50% and 2.32%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Evolus Reports Second Quarter 2021 Results and Provides Business Update

Record Quarter: Net Revenue Grew 235% Year-over-Year to $26.1 Million

5 months ago - GlobeNewsWire

Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know

Evolus, Inc. (EOLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

Can Evolus Disrupt the Botox Market?

This small-cap stock is going after a billion-dollar market.

6 months ago - The Motley Fool

Evolus Announces Appointment of David K. Erickson as Vice President, Investor Relations

NEWPORT BEACH, Calif., June 30, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (Nasdaq: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today ann...

6 months ago - GlobeNewsWire

Peer Reviewed Article Highlights Efficacy and Safety of Jeuveau® in Patients with Skin of Color

NEWPORT BEACH, Calif., June 24, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (Nasdaq: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today ann...

7 months ago - GlobeNewsWire

Evolus Appoints Dan Stewart as Vice President and General Manager, International

NEWPORT BEACH, Calif., May 19, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (Nasdaq: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today anno...

8 months ago - GlobeNewsWire

Evolus Reports First Quarter 2021 Results and Provides Business Update

Q1 2021 Net Revenues of $12.2 million, Despite Half-Quarter ITC Impact

8 months ago - GlobeNewsWire

Repeat Doses Of Evolus' Frown Lines Treatment Are Safe, With Decreasing Rates Of Adverse Events

Evolus Inc (NASDAQ: EOLS) has announced two newly published peer review studies in Aesthetic Surgery Journal that provide supportive evidence of the safety and efficacy of repeat doses of prabotulinumto...

8 months ago - Benzinga

Why Evolus (EOLS) Might Surprise This Earnings Season

Evolus (EOLS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

8 months ago - Zacks Investment Research

Evolus to Report First Quarter 2021 Results and Provide Business Update

NEWPORT BEACH, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, announced ...

8 months ago - GlobeNewsWire

Evolus, Inc. (EOLS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Evolus, Inc. (EOLS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

8 months ago - Zacks Investment Research

Why Evolus Stock Dived by Almost 19% Today

Few are smiling about the company's upcoming share issue.

9 months ago - The Motley Fool